erlotinib.md

Erlotinib

Tarceva 150mg

臨採

TAH Drug Code	OTAR1
Indications	Indicated for first-line and maintenance treatment in patients with locally invasive or metastatic non-small cell lung cancer (NSCLC) with EGFR-TK mutations. Also applicable as second-line therapy for patients with lung adenocarcinoma who have previously undergone chemotherapy but still experience local deterioration or metastasis.
Dosing	[Non–small cell lung cancer (NSCLC) (as first-line therapy, maintenance treatment, or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.
Hepatic Impairment	Dose adjustment required
Renal Impairment	Dose adjustment not necessary
Contraindications	Hypersensitivity to any component of the formulation.
Adverse Effects	Common: Edema (37%), Alopecia (14%), Pruritus (13-16%), Rash, Any grade (60-85%), Weight decreased (39%), Abdominal pain (11-46%), Diarrhea, Any grade (20-62%), Flatulence (13%), Indigestion (17%), Inflammatory disease of mucous membrane (17-22%), Loss of appetite (52%), Nausea (33-60%), Vomiting (23-42%), Hyperbilirubinemia, Increased liver enzymes, Infectious disease (24-39%), Bone pain (25%), Myalgia (21%), Headache (15%), Conjunctivitis (12-18%), Keratoconjunctivitis sicca (12%), Anxiety (13%), Depression (19%), Cough (16-48%), Dyspnea, Any grade (41-45%), Fatigue (52%), Fever (36%) Serious: Cardiac dysrhythmia (Grade 3 or higher), Myocardial infarction, Syncope (Grade 3 or higher), Rash (Grade 3 or 4) (5-14%), Stevens-Johnson syndrome, Toxic epidermal necrolysis, Bowel obstruction (Grade 3 or higher), Diarrhea (Grade 3 or 4) ( 2-5%), Gastrointestinal hemorrhage, Gastrointestinal perforation, Pancreatitis (Grade 3 or higher), Deep venous thrombosis (3.9%), Microangiopathic hemolytic anemia, With thrombocytopenia (up to 1.4%), Hepatorenal syndrome, Liver failure, Cerebrovascular accident (2.5%), Corneal ulcer, Perforation of cornea, Acute renal failure, Dyspnea (Grade 3 or 4) (8-17%), Interstitial lung disease
Pregnancy	Human (and Animal) Data Suggest Risk
Lactation	No (Limited) Human Data - Potential Toxicity
More Info	UpToDate